Wire · opportunities
GSK's Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
GSK’s partnered antibody-drug conjugate risvutatug rezetecan demonstrated a median overall survival of 18.5 months in a Chinese phase 3 trial for relapsed small cell lung cancer, outperforming chemotherapy and rival treatments from Amgen and Merck. GSK plans to publish global phase 3 trial data in 2027, highlighting potential safety advantages over competitors.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can position your lung cancer treatment strategy around GSK's ADC leveraging China trial data with safety edges, giving you a route to challenge incumbents globally. Urgent competitor mapping in that niche now will reveal openings created by their slower global timelines.
◆ Coverage
1 source · 12 Sep 2026
◆ Related on Wire
◆ Topics